24/7 Customer Support
The respiratory syncytial virus market is expected to reach revenue of US$ 4,202.6 million by 2027, growing at a CAGR of 14.9% over the forecast period 2022-2027. The market growth over the forecast period reflects the recovery of the industry from Covid-19 and the subsequent shift in the growth trend. The respiratory syncytial virus market is estimated to account for a revenue of US$ 1,823.3 Million in 2021.
The report provides market size estimates for the global respiratory syncytial virus market for the period of 2017 to 2027, wherein 2017-2020 are historic years, 2021 is considered as the base year, and 2022-2027 as the forecast period. The research report offers analysis explained across 18 chapters totaling 260 pages, with 39 extensive data tables and 77 figures.
Respiratory Syncytial Virus is also known as Human respiratory syncytial virus is a contagious virus that affects the respiratory tract and increases the lung's infection in the body. The virus is mostly found in children. According to the Centers for Disease Control and Prevention (CDC), One to two out of every 100 children younger than 6 months of age with RSV infection may need to be hospitalized. As per data provided by the National Institute of Health (NIH), globally RSV affects more than 64 million people each year. The report on the Global Respiratory Syncytial Virus (RSV) market provides a comprehensive analysis of market opportunities, market dynamics, and the competitive landscape of the industry.
According to the findings, the global respiratory syncytial virus burden was 33.1 million in 2015, resulting in 3.2 million hospitalizations and 59,600 child deaths. Respiratory syncytial virus, as per the Centers for Disease Control and Prevention (CDC), can cause hospitalizations in one to two out of every hundred children under the age of six months. RSV has few medications available and just a few have been approved by the Food and Drug Administration (FDA). Due to its property of broad spectrum of antiviral action in vitro, where it suppresses RSV replication, Virazole has been approved by the FDA and is predicted to see demand growth at the highest CAGR of nearly 16% amongst the available drugs. Moreover, there are several steps taken by the government for the management and control of respiratory syncytial viral infection. These government-supported proactive welfare programs are creating lucrative opportunities for market growth. For instance, in order to reduce the burden of RSV infections, the World Health Organization initiated a new campaign called the BRaVe (Battle Against Respiratory Viruses) initiative. The BRaVe Initiative is aimed at catalyzing multidisciplinary research on strategies to prevent and treat medically important respiratory virus infections, with the goal of incorporating scientific advances and technical innovations into public health practice as soon as possible. Though the respiratory syncytial virus is a rare disorder; its impact can be seen around the globe. Among the different geographic regions studied in the report, North America is projected to have the largest share, around 38%. The high share is due to the high rate of infection in the area. In the United States alone, nearly all children become infected with RSV by age 2, with 75,000 to 125,000 of them hospitalized each year. Furthermore, increased access to treatment is projected to boost demand for respiratory syncytial virus medicines in the region.
The research report provides an in-depth analysis of the market opportunities in the global respiratory syncytial virus market. Geographically, the market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. As per analysis, Asia-Pacific is seen as a fast-growing regional market, with rising respiratory syncytial virus infection rates and increased healthcare awareness.
The research report provides respiratory syncytial virus market analysis on the basis of the following parameters – Drug Type, Dosage Form, Treatment Type, and Distribution Channel. The extensive segmentation allows individuals or businesses associated with the RSV market to identify the right market for their products.
The report also elaborates on understanding value chain analysis, explains global and regional opportunities, and market dynamics. Porter's five forces analysis in the report explains the impact of individual elements on the global respiratory syncytial virus market growth trends, such as supplier bargaining power, competitor competitive intensity, threat of new entrants, threat of substitutes, and buyer bargaining power. Analysis of key factors like political, economic, social, technological, legal, and environmental affecting the respiratory syncytial virus market, has been covered under the PESTLE analysis section. The report includes a Covid-19 impact study and a comprehensive chapter of profiles of key players active in the RSV market.
The global respiratory syncytial virus market size is expected to reach $4,202.6 Mn by 2027. The pandemic has brought in a revolutionary shift in the healthcare industry. Life science companies are involving end-users in trials and drug designs, and companies are inevitably relying on the latest pharmaceutical innovations to create digitally-driven medical solutions. Seasonal viruses, such as respiratory syncytial virus, spread through similar channels to Covid-19, and public health authorities and the government are taking effective measures to control the spread. The report includes a covid-19 impact study, providing a shift in growth trends for both pre-covid and post covid sentiments.
The market has observed tremendous growth with the increasing prevalence of respiratory syncytial virus and the development of targeted therapies is propelling the growth of the global respiratory syncytial virus market. Targeted therapies like monoclonal antibody-related therapies whose repetitive treatment reduces hospitalization cases to more than half. Conversely, the advanced technologies used in the treatment regimens are responsible for increasing the cost of various treatments. Also, the lack of availability of point-of-care (POC) diagnostic instruments is a major barrier in the growth of the market, as the virus medicines are mostly available in developed regions such as North and South America and Europe.
The competition landscape section of the report offers an in-depth analysis of key players active in the global respiratory syncytial virus market. Details covered for these players include – Business Description, Product Portfolio, Company Financials and Claims, Key Details, Strategy Outlook, and Recent Developments. The players profiled in the research report are as follows – AbbVie, Inc, AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc, Enanta Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Johnson & Johnson's, mAbxience, Merck Co., Inc., Pfizer Inc., and Sanofi.
By Drug Type
By Dosage Form
By Treatment Type
By Distribution Channel
|Market Size Value in 2021||US$ 1,823.3 Mn|
|Expected Revenue in 2027||US$ 4,202.6 Mn|
|Unit||Value (USD Mn)|
|Segments covered||By Drug Type, By Dosage Form, By Treatment Type, By Distribution Channel|
|Key Companies||AbbVie, Inc, AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc, Enanta Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Johnson & Johnson's, mAbxience, Merck Co., Inc., Pfizer Inc., and Sanofi.|
|Customization Scope||Get your customized report as per your preference. Ask for customization|
The Global Respiratory Syncytial Virus Market is expected to reach US$ 4,202.6 Million by 2027.
The current size of the Global Respiratory Syncytial Virus Market is US$ 1,669.5 Million.
High cost of technology and inaccessibility of diagnostic facilities are some factors hampering the growth of the market.
The Global Respiratory Syncytial Virus Market is expected to grow at a CAGR of 14.9% in terms of revenue in the forecasted period.
Increased disease prevalence and advent of targeted therapies are major drivers to the Global Respiratory Syncytial Virus Market.
North America is the largest shareholder in the market.
Injectable type of dosage holds the highest share in the Global Respiratory Syncytial Virus Market.
Key players of the Global Respiratory Syncytial Virus Market are AstraZeneca PLC, Atea Pharmaceuticals, Bausch Health Companies Inc., Celltrion Inc., Enanta Pharmaceuticals, Inc and Others.
The report provides market size estimates for period of 2017-2027. Wherein, 2017-2019 is the historic period. 2020 is the base year, and 2021-2027 is the forecast period. In all, forecast is provided for a term of six years in the report.
Rising R&D expenditure in the healthcare sectors and increasing respiratory tract diseases among children and elderly are the trends to the Global Respiratory Syncytial Virus Market.
Based on distribution channel, the market is segmented into hospital pharmacies, dug stores, Retail pharmacies and clinics.